Blockchain Registration Transaction Record

Helix BioPharma Extends LEUMUNA Option with MetaShape Through 2028

Helix BioPharma extends its LEUMUNA option agreement with MetaShape Pharma through 2028, advancing MS 001 as a co-therapy for obesity and metabolic diseases.

This news matters because it highlights advancements in metabolic disease treatment, particularly obesity, which affects millions globally and is linked to serious health issues like diabetes and heart disease. Current GLP-1 therapies, while effective, often face challenges with weight regain and non-selective fat loss. The extension of the agreement for MS 001, a co-therapy designed to enhance fat-selective weight loss and durability, could lead to more effective and sustainable treatments. By targeting NAD+ biology and mitochondrial function, it addresses metabolic dysfunction at a cellular level, potentially improving patient outcomes and reducing healthcare burdens. For investors, this signals Helix BioPharma's strategic diversification beyond oncology into high-value metabolic indications, enhancing its pipeline and long-term growth prospects.